These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 33757574)

  • 1. Emerging agents and regimens for AML.
    Liu H
    J Hematol Oncol; 2021 Mar; 14(1):49. PubMed ID: 33757574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
    Bose P; Vachhani P; Cortes JE
    Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
    Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
    Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia.
    Chen KTJ; Gilabert-Oriol R; Bally MB; Leung AWY
    Pharm Res; 2019 Jun; 36(9):125. PubMed ID: 31236772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and emerging therapies for acute myeloid leukemia.
    Robak T; Wierzbowska A
    Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician.
    Lai C; Bhansali RS; Kuo EJ; Mannis G; Lin RJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390018. PubMed ID: 37155946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation.
    Mathisen MS; Kantarjian H; Jabbour E; Garcia-Manero G; Ravandi F; Faderl S; Borthakur G; Cortes JE; Quintás-Cardama A
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):139-43. PubMed ID: 23276886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A User's Guide to Novel Therapies for Acute Myeloid Leukemia.
    Patel SA; Gerber JM
    Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):277-288. PubMed ID: 32113891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
    Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in targeted therapies in acute myeloid leukemia.
    Bhansali RS; Pratz KW; Lai C
    J Hematol Oncol; 2023 Mar; 16(1):29. PubMed ID: 36966300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The landscape of novel strategies for acute myeloid leukemia treatment: Therapeutic trends, challenges, and future directions.
    Wu RH; Zhu CY; Yu PH; Ma Y; Hussain L; Naranmandura H; Wang QQ
    Toxicol Appl Pharmacol; 2023 Aug; 473():116585. PubMed ID: 37302559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
    Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
    Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift.
    Kopmar NE; Estey EH
    Clin Adv Hematol Oncol; 2019 Oct; 17(10):569-575. PubMed ID: 31730583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
    McMahon CM; Perl AE
    Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Xuan L; Liu Q
    J Hematol Oncol; 2021 Jan; 14(1):4. PubMed ID: 33407700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The outcomes of relapsed acute myeloid leukemia in children: Results from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05R study.
    Moritake H; Tanaka S; Miyamura T; Nakayama H; Shiba N; Shimada A; Terui K; Yuza Y; Koh K; Goto H; Kakuda H; Saito A; Hasegawa D; Iwamoto S; Taga T; Adachi S; Tomizawa D
    Pediatr Blood Cancer; 2021 Jan; 68(1):e28736. PubMed ID: 32991072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
    Griffiths EA; Carraway HE; Chandhok NS; Prebet T
    Leuk Res; 2020 Apr; 91():106339. PubMed ID: 32146154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges.
    Short NJ; Konopleva M; Kadia TM; Borthakur G; Ravandi F; DiNardo CD; Daver N
    Cancer Discov; 2020 Apr; 10(4):506-525. PubMed ID: 32014868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.
    Cui L; Liu Y; Pang Y; Qian T; Quan L; Cheng Z; Dai Y; Ye X; Pang Y; Shi J; Ke X; Wu D; Fu L
    Cancer Gene Ther; 2020 Feb; 27(1-2):1-14. PubMed ID: 31292516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.